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Purpose: Even though the importance of micrometastases (MMS) and isolated tumor cells (ITC) has been brought up by 
many physicians, its impact on the prognosis in stage II colorectal cancer is uncertain. In this research, we tried to investi-
gate the clinical features of MMS and ITC and to prove any correlation with prognosis.
Methods: The research pool was 124 colorectal cancer patients who underwent a curative resection from April 2005 to 
November 2009. A total of 2,379 lymph nodes (LNs) were examined, and all retrieved LNs were evaluated by immunohis-
tochemical staining with anti-cytokeratin antibody panel. Clinicopathologic parameters and survival rates were compared 
based on the presence of MMS or ITC and on the micrometastatic lymph node ratio (mmLNR), which is defined as the 
number of micrometastatic LNs divided by the number of retrieved LNs.
Results: Out of 124 patients (26.6%) 33 were found to have MMS or ITC. There were no significant differences in clinico-
pathologic features, such as gender, tumor location and size, depth of invasion, histologic grade, except for age (P = 0.04). 
The three-year disease-free survival rate for the MMS or ITC positive group was 85.7%, and that for MMS and ITC nega-
tive group was 92.8% (P = 0.209). The three-year disease-free survival rate for the mmLNR > 0.25 group was 73.3%, and 
that for the mmLNR ≤ 0.25 group was 92.9% (P = 0.03).
Conclusion: The presence of MMS or ITC was not closely correlated to the prognosis. However, mmLNR is thought to be 
a valuable marker of prognosis in cases of stage II colorectal cancer.
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tion grade, serum level of carcinoembrionic antigen (CEA), tumor 
deposits, circumferential resection margin, perineural infiltration, 
lymphatic or vascular invasion, DNA ploidy, expression level of 
proliferating cell nuclear antigen (PCNA), K-ras mutation, 18q loss 
of heterozygosity (LOH) analysis, tumor regression grade, micro-
satellite instability (MSI), etc. have been suggested to be factors as-
sociated with prognosis [2-4]. Among them, one of the most im-
portant prognostic factors is lymph node metastasis. Together with 
the infiltration level of the gut wall, the status of lymph node me-
tastasis is applied to determine Duke’s staging and TNM staging, 
and it also provides important information to clinicians for estab-
lishing the treatment plan, such as adjuvant chemotherapy [5].
Lymph node metastasis is an important prognostic factor for re-
currence. Nonetheless, Adell et al. [6], Broll et al. [7], and Chen 
and Bilchik [8] reported that in 20-30% of patients without lymph 
node metastasis, the disease recurred within 5 years after a radical 
resection, and as one of prognostic factors for such recurrence, 
lymph node micrometastasis was mentioned. Generally, for the 
detection of lymph node metastasis, hematoxylin-eosin (H&E) 
staining has been used. It has been reported to be limited to detect-
INTRODUCTION
In Korea, not only is the incidence of colorectal cancer second high-
est among gastrointestinal malignant tumors, colorectal cancer is 
also an important disease that is on the increase every year [1]. As 
interest in the treatment of and the prognosis for colorectal cancer 
is on the rise, efforts to obtain a prognosis for colorectal cancer have 
been made continuously, and among them, TNM staging has been 
generally used as a prognosis predictor. In patients without distant 
metastasis, infiltration level of the gut wall, pathologic differentia-
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ing lymph node micrometastases such as isolated tumor cells. Be-
cause of lymph node micrometastasis that was not detected by H& 
E staining, cancer staging was underestimated, and the patient was 
not treated properly, which may have been associated with recur-
rence or distant metastasis [7-10]. To overcome such limitations 
and to detect lymph node metastasis, several methods have been 
investigated. The representative methods are immunohistochem-
istry, staining using antibody to antigens expressed in tumor cells, 
and the reverse transcription polymerase chain reaction (RT-PCR), 
which applies molecular biological techniques. Nevertheless, until 
now, whether lymph node micrometastasis detected by such meth-
ods is associated with the prognosis for colorectal cancer is still con-
troversial [7, 8].
In this study, in colorectal cancer patients in whom lymph node 
metastasis was not detected by conventional H&E staining, the ef-
fect of micrometastasis and isolated tumor cells on the prognosis 
for the patients was addressed by examining the rate of detection 
of micrometastasis and isolated tumor cells with immunohisto-
chemical staining methods using an anti-cytokeratin antibody panel 
and by analyzing the clinical features of the subject patients.
METHODS
Study subjects
Selected from patients who underwent a radical resection for an 
adenocarcinoma that had developed in the large intestine and the 
rectum from April 2005 to November 2008, the patients in this 
study were those in whom lymph node metastasis had not been 
detected by using histopathological tests and in whom the primary 
tumors had passed through the intestinal proper muscle layer. Based 
on the medical records of the subject patients, the gender of the 
patients, their age, other associated diseases, the presence or ab-
sence of bowel obstruction and perforation at the time of surgery, 
the location, size, Borrmann type, infiltration level, differentiation 
grade, lymphovascular invasion of the tumor, the number of re-
sected lymph nodes, as clinical variables and pathological charac-
teristics were examined. For the clinical analysis, patients who had 
undergone surgery for other cancers previously, patients suspected 
of having hereditary colorectal cancer, and patients treated with 
chemo-radiation therapy prior to surgery were excluded.
After radical resection, at 3- to 6-month intervals, follow-ups were 
performed by checking the CEA level, chest and abdominopelvic 
computed tomography, and colonoscopy. Patients whose follow-
ups were not clear, recurrence, death, and the time of death were 
assessed by individual telephone interviews. The median follow-
up period was 36 months (range, 1 to 62 months).
Pathological methods
During the study period, the number of sequentially registered 
subject patients was 124. A total of 2,379 lymph nodes were re-
sected, and an average of 19 lymph nodes per patient was exam-
ined. An additional section, 4 μm in thickness, was taken once 
from all resected lymph nodes, and using Lab Vision Autostainer 
480S (Thermo, Astmoor Runcorn, UK), immunohistochemical 
staining was performed with the primary antibody anti-cytokera-
tin cocktail (AE1/AE3; Biogenex, San Ramon, CA, USA).
Lymph node micrometastasis was separately defined according 
to the size of tumor cells in the lymph nodes after immunohisto-
chemical staining as isolated tumor cells (ITC) when the size was 
less than 0.2 mm and as micrometastasis (MMS) when the size was 
between 0.2 mm and less than 2 mm (Figs. 1, 2) [11]. The micro-
metastasis lymph node ratio (mmLNR) was calculated by dividing 
the number of lymph nodes in which lymph node micrometasta-
sis was detected by the total number of resected lymph nodes.
Statistics
The association of lymph node micrometastasis with other prog-
nostic factors, as well as with the effect of lymph node microme-
A B
Fig. 1. (A) Foci of nodal micrometastases detected with haematoxylin-eosin (H&E, × 200). (B) Foci of nodal micrometastases detected with 
immunohistochemistry for cytokeratin (IHC, × 200).Journal of The Korean Society of
Coloproctology
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tastasis on recurrence and death, were analyzed. SPSS ver. 14.0 
(SPSS Inc, Chicago, IL, USA) was used. For the analysis of cate-
gorical variables, Fisher’s exact test or the chi-square test was used. 
For the analysis of continuous variables, depending on the normal-
ity of the variables, the independent variable t-test or the Mann-
Whitney U test was used. For the analysis of the mortality rate, the 
Kaplan-Meier test was used, and the mortality rate was analyzed 
by using the log rank method. For the multivariate regression anal-
ysis, the Cox proportional hazard model was used. Variables, in-
cluding age and gender, whose significant levels were lower than 
0.05 in the univariate analysis, were included in the analysis of the 
variables. In all analyses, a significance level lower than 0.05 was 
determined to be statistically significant.
RESULTS
Clinical features of lymph node micrometastasis
The study subjects were 124 patients, their mean age was 61.2 years 
(± 11.6), and the ratio of males and females was 81:43. From the 
subject patients, a total of 2,379 lymph nodes were resected, and 
lymph node micrometastasis was detected in 148 of those lymph 
nodes (6.3%). Of the 124 patients, micrometastasis was detected 
in 33 patients (26.6%) (Table 1). Among the detected lymph node 
metastases, micrometastasis larger than 0.2 mm but smaller than 
2 mm was detected in 2 of the 124 patients (1.6%), and the num-
ber of lymph nodes with micrometastasis was 2 (0.08%). Isolated 
tumor cells that were smaller than 0.2 mm were detected in 31 pa-
tients (25%) and the number of lymph node with isolated tumor 
cells was 146 (6.14%). In none of the patients were micrometasta-
sis and isolated tumor cells detected simultaneously. In the median 
value per patient 4 lymph nodes (range, 1 to 14), micro lymph node 
metastasis was detected, and the median value of the lymph node 
micrometastasis rate was 0.2 (range, 0.02 to 0.63). Among the 124 
subject patients, 109 patients had lymph node micrometastasis 
Table 1. Clinicopathologic characteristics according to presence of 
micrometastases or isolated tumor cells
Variable Patients MMS and ITC 
negative
MMS or ITC 
positive
P-value
Total 124 91 (73.4) 33 (26.6)
Gender 0.506
   Male   81 61 (67.0) 20 (60.6)
   Female   43 30 (33.0) 13 (39.4)
Age (yr)   61.2 ± 11.6 0.04
ASA score 0.641
   <3   94 70 (76.9) 24 (72.7)
   > =3   30 21 (23.1)   9 (27.3)
Location 0.84
   Colon   61 44 (48.4) 17 (51.5)
   Rectum   63 47 (51.6) 16 (48.5)
Borrmann type 0.644
   I, II   93 67 (73.6) 26 (78.8)
   III, IV   31 24 (26.4)   7 (21.2)
Obstruction     8 6 (6.6) 2 (6.1) 1
Perforation     2 1 (1.1) 1 (3.0) 0.463
Histologic grade 1
   G1, 2 120 88 (96.7) 32 (97.0)
   G3, 4     4 3 (3.3) 1 (3.0)
Tumor size (cm)   5.7 ± 2.1 0.845
Depth of invasion 0.083
   T3 116 87 (96.7) 29 (87.9)
   T4     7 3 (3.3)   4 (12.1)
Retrieved LN 19.2 ± 9.8 0.29
LVN invasion   48 31 (34.1) 17 (51.5) 0.096
Chemotherapy 0.383
   None   17 11 (12.1)   6 (18.2)
   FL 105 79 (86.8) 26 (78.9)
   FOLFOX     2 1 (1.1) 1 (2.9)
Values are presented as number (%) or mean ± SD.
MMS, micrometastasis; ITC, isolated tumor cells; ASA, American Society of Anesthe-
siologists; G1, well differentiated; G2, moderately differentiated; G3, poorly differ-
entiated; G4, undifferentiated or signet ring cell; LN, lymph node; LVN, lymphovas-
cular nerve; FL, fluorouracil + leucovorin; FOLFOX, folinic acid (leucovorin) + fluo-
rouracil + oxaliplatin.
Fig. 2. Foci of isolated tumor cells detected with immunohistochem-
ical staining (IHC, × 400).
rates lower than 0.25, and 15 patients had rates higher than 0.25 
(Table 2).
During the follow-up observation period, recurrence was con-
firmed in 12 patients, and 7 patients expired. In regard to recur-
rence sites, liver metastasis were seen in 9 cases (75%), which was 
the most prevalent, pulmonary metastasis in 1 case and local recur-
rence in 2 cases (Table 3). Among the 7 patients who succumbed Journal of The Korean Society of
Coloproctology
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to the disease, the cause of death in 5 cases was death pertinent to 
colorectal cancer, the cause of death in another case was primary 
lung cancer detected during the follow-up observation, and the 
cause of death in the last case was postsurgical sepsis.
Association of lymph node micrometastasis with other 
prognostic factors
The patient group in which lymph node micrometastasis had been 
detected and the patient group in which no lymph node microme-
tastasis had been detected were compared. It was observed that 
the mean age of the patient group with lymph node micrometas-
tasis was 64.9 years (± 10.2), which was higher than the 59.8 years 
(± 11.6) for the group without lymph node micrometastasis (P = 
0.04). Nonetheless, other than that, gender, the location and the 
size of the tumors, the invasion level to the gut wall, the Borrmann 
type, the pathologic differentiation grade, the number of resected 
lymph nodes, the presence of absence of lymphatic or vascular in-
vasion, the presence or absence of bowel obstruction or bowel per-
foration, and the ASA grade of the two groups showed no statisti-
cally significant differences (Table 1).
Lymph node micrometastasis and recurrence
When the 3-year disease-free survival of the patient group with-
out lymph node micrometastasis was compared with that of the 
patient group with lymph node micrometastasis, it was 92.8% and 
64.2%, respectively, and a tendency for the disease-free survival 
rate of the group with lymph node micrometastasis to be low was 
shown; nonetheless, the difference was not statistically significant 
(P = 0.056) (Fig. 3). When the disease-free survival rate was com-
pared based on the mmLNR, in the cases with mmLNR > 0.25, 
the 3-year disease-free survival rate was 73.3%, which was signifi-
cantly lower than the 92.9% for the cases with mmLNR < = 0.25 (P 
= 0.03) (Fig. 4). 
When the effects on recurrence were analyzed by using a univar-
iate regression analysis, Borrmann type higher than III (hazard 
ratio [HR], 3.19; 95% confidence interval [CI], 1.03 to 9.9; P = 
0.044) and mmLNR > 0.25 (HR, 3.91; 95% CI, 1.03 to 14.82; P = 
0.045) were found to be significant risk factors for recurrence, and 
no other variables were found to be significant (Table 4). In the 
multivariate analysis, similarly, Borrmann type higher than III 
(HR, 4.46; 95% CI, 1.32 to 15.16; P = 0.02) and mmLNR > 0.25 
(HR, 4.74; 95% CI, 1.22 to 18.47; P = 0.03) were found to be inde-
pendent prognostic factors for recurrence (Table 4).
Lymph node micrometastasis and survival rate
The overall 3-year survival rate pertinent to colorectal cancer of 
the group with lymph node micrometastasis was 96.3%, but it was 
not significantly different from the 97.6% for the group without 
lymph node micrometastasis (P = 0.75) (Fig. 3). When the 124 sub-
Table 2. Patient number according to micrometastasis lymph node ratio
mmLNR < = 0.25 mmLNR > 0.25
Total 109 15
MMS or ITC positive   18 15
Mean mmLNR  0.02 ± 0.06 0.42 ± 0.19
MMS, micrometastasis; ITC, isolated tumor cells; mmLNR, micrometastasis lymph 
node ratio.
Table 3. Patient numbers for distant metastasis and local recurrence
MMS or ITC negative MMS and ITC positive
Total 7 5
Distant metastasis
   Liver 6 3
   Lung 1 0
Local recurrence 0 2
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Fig. 3. Survival according to presence of micrometastases or isolated tumor cells: (A) disease-free survival and (B) overall survival. MMS, mi-
crometastasis; ITC, isolated tumor cells.Journal of The Korean Society of
Coloproctology
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ject patients were analyzed based on a micrometastasis lymph node 
ratio of 0.25, the overall 3-year survival rate was 90.9% in the 
cases with mmLNR > 0.25, a relatively low survival rate in com-
parison with the 98.0% for the cases with mmLNR < = 0.25, but this 
result was not statistically significant (P = 0.15) (Fig. 4).
DISCUSSION
In colorectal cancer, lymph node metastasis is not only an impor-
tant prognostic factor but also an important criterion to determine 
whether or not to administer postsurgical adjuvant therapies and 
to choose adjuvant therapies. With the development of medical 
techniques, histopathological equipment and methods, small-sized 
tumor cells that could not be detected by conventional H&E stain-
ing could be detected, and such cells were termed as micrometas-
tasis and began to be investigated. The term micrometastasis was 
used in breast cancer for the first time and referred to lymph node 
lesions smaller than 2 mm. In breast cancer, the usefulness of mi-
crometastasis has been proven, so it has been used widely for the 
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Fig. 4. Survival according to micrometastasis lymph node ratio (mmLNR): (A) disease-free survival and (B) overall survival.
Table 4. Factors associated with recurrence in stage II colorectal cancer (uni- and multi-variate analysis)
Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Gender (Female) 0.74 0.19-2.8 0.661 0.82 0.21-3.16 0.78
Age > 60 yr 1.67 0.5-5.54 0.405 1.31 0.38-4.58 0.67
ASA > = 3  1.57 0.47-5.23 0.459
Location (Rectum) 1.31 0.42-4.14 0.642
Borrmann type III, IV 3.19 1.03-9.9 0.044 4.46 1.32-15.16 0.02
Histologic grade > = G3
a 0.047 0.0-108.2 0.675
Obstruction (+) 1.61 0.21-12.45 0.65
Perforation (+) 5.54 0.71-43.1 0.102
Tumor size > 5 cm 3.74 0.82-17.07 0.089
Depth of invasion T4 1.79 0.23-13.87 0.579
Retrieved LNs < 12 0.78 0.17-3.55 0.745
LVN invasion (+) 1.14 0.36-3.61 0.818
Chemotherapy (+) 0.73 0.09-5.69 0.766
MMS (+) or ITC (+) 3.01 0.92-9.83 0.069
mmLNR > 0.25 3.91 1.03-14.82 0.045 4.74 1.22-18.47 0.03
aG3 is poorly differentiated.
CI, confidence interval; ASA, American Society of Anesthesiologists; G3 is poorly differentiated; LVN, lymphovascular nerve; MMS, micrometastasis; ITC, isolated tumor 
cells; mmLNR, micrometastasis lymph node ratio.Journal of The Korean Society of
Coloproctology
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tal cancer, the clinical features of micrometastases have not been 
reported abundantly, and a consensus on the association between 
micrometastasis and prognosis has not been reached. According 
to the American Joint Committee on Cancer, in colorectal cancer, 
similar to breast cancer, lesions 0.2-2.0 mm in diameter are defined 
as micrometastases, and lesions smaller than 0.2 mm are defined 
as isolated tumor cells [11]. Nevertheless, such a definition accord-
ing to the size cannot be applied to molecular biology methods 
such as RT-PCR; thus, it has been proposed that they be referred 
to as occult tumor cells or occult lymph node metastases. In addi-
tion, different results for their correlation to prognosis, depending 
on the methods, have been observed, so integrated comprehen-
sive studies are required [13-15].
In recent studies, Park et al. [16] reported that no effect on prog-
nosis of micrometastases detected in stage 1 or 2 colorectal cancer 
by H&E staining and immunohistochemical staining was observed 
and that only previously known factors, such as lymphatic invasion 
and the number of resected lymph nodes, were associated with 
prognosis. Lee et al. [17] reported that isolated tumor cells in stage 
1 or 2 colorectal cancer patients detected by immunohistochemi-
cal staining did not affect prognosis (P = 0.981). On the other hand, 
Bosch et al. [18] reported that in 39 stage 2 colorectal cancer pa-
tients without lymph node metastasis, micrometastases or isolated 
tumor cells, which were thought to be occult metastatic lesions of 
the lymph node, were examined by immunohistochemical stain-
ing, and the group in which micrometastasis or isolated tumor cells 
had been detected was found to show a statistically significantly 
lower overall survival rate compared to the group in which micro-
metastases or isolated tumor cells had not been detected (P = 0.006).
On the other hand, Liefers et al. [9], who used RT-PCT as a patho-
logical method, reported that lymph node micrometastasis was 
detected in 54% of the examined stage 2 colorectal patients, and 
when their 5-year survival rates were compared, it was 50% in the 
group with lymph node micrometastasis and 91% in the group 
without lymph node micrometastasis, a statistically significant dif-
ference (P = 0.02). Thus, lymph node micrometastasis may be as-
sociated with prognosis. In an interim report of a recently ongo-
ing prospective study conducted on the usefulness of lymph node 
micrometastasis in colorectal cancer, Bilchik et al. [15] reported 
that in the patient group in which lymph node micrometastasis 
was not detected through the use of H&E staining, immunohisto-
chemical staining, and RT-PCR, recurrence was detected in none 
of the cases during the follow-up observation period, and in the 
patient group in which lymph node micrometastasis was detected 
for more than one technique, recurrences were more abundant. 
Thus, after a sufficient follow-up observation period, significant 
results should be shown in the final report.
In pathological test methods, different results are shown accord-
ing to the frequency of taking additional sections. In the results 
reported by Lee et al. [17], sectioning was performed once for H&E 
staining and immunohistochemical staining, and isolated tumor 
cells had no effect on prognosis. On the other hand, in the result 
reported by Yasuda et al. [19], sectioning, 3 μm in thickness, was 
performed once for H&E staining and sectioning, 6 μm in thick-
ness, was performed 5 times for immunohistochemical staining, 
and lymph node micrometastasis was statistically significantly as-
sociated with prognosis. Verrill et al. [20] reported that in 100 
colorectal cancer patients, in addition to conventional lymph node 
sectioning, additional sectioning at 100 μm intervals was performed 
twice; thus, sectioning was performed three times, stage of 12 pa-
tients was upstaged. In 3 of those patients, lymph node metastasis 
was newly detected; thus, the disease stage, pN0, was adjusted to   
a pN1 disease stage. In recently reported studies on lymph node 
micrometastasis, results have been reported for sectioning repeated 
for from 5 to as many as 10 times. Multiple lymph node section-
ing has been reported to not only raise the rate of the detection of 
lymph node micrometastasis but also to make clearer the associa-
tion of disease stage with prognosis [19, 21]. In addition, in order 
to improve the quality of pathological tests, Brown et al. [22] used 
lymph node fat clearing techniques, and at that time, the number 
of resected lymph node was increased and the TNM stage (pN) 
was upstaged in some cases. Therefore, for the detection of occult 
lymph node metastasis, not only is the precise resection of lymph 
nodes thought to be required, but also an increase in the number 
of sectionings may be of help. Nevertheless, for the fact that such 
procedures require long time, high cost, and more personnel should 
be kept in mind.
Recently, instead of N disease stage, which could be readily in-
fluenced by the range of lymph node resection during surgery, the 
experience level of the surgeon and the level of extraction of lymph 
nodes from specimens, attention has been paid to the lymph node 
ratio (LNR), which is the ratio of the number of metastatic lymph 
nodes to the total number of resected lymph nodes because of its 
association with prognosis and its importance [23-25]. Telian and 
Bilchik [25] reported significant differences in the recurrence rates 
and the survival rates based on a lymph node ratio of 0.25 in stage 
3 colorectal cancer patients. Wang et al. [26] reported that the prog-
noses of 24,477 stage 3 colorectal cancer patients who were regis-
tered in the Surveillance, Epidemiology, and End Result (SEER) 
cancer registry were significantly different, depending on lymph 
node ratio, which they divided into four groups. Nonetheless, the 
concept of such a ratio has not been applied to studies on lymph 
node micrometastasis in stage 2 colorectal cancer patients.
In our study, the concept of the mmLNR was applied to lymph 
node micrometastases that were detected by adding one additional 
sectioning, and it was observed that lymph node micrometastasis 
was statistically significantly associated with recurrence in stage 2 
colorectal cancer patients. When the cost and the time required to 
section lymph nodes several times or to perform RT-PCR to de-
tect lymph node micrometastasis are considered, from a practical 
point of view, it is anticipated that it may become a useful prognos-
tic factor that can be readily applied. Nonetheless, considering the 
relatively short follow-up observation of our study, longer, prospec-
tive, and multicenter studies are thought to be required.Journal of The Korean Society of
Coloproctology
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Impact of metastatic lymph node ratio in node-positive colorectal 
cancer. World J Gastrointest Surg 2010;2:70-7.
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By analyzing not only the presence and number of lymph node 
micrometastasis but also the mmLNR for the prediction of the 
prognosis in stage II colorectal cancer patients, the usefulness and 
the possibility of a clinical approach using the mmLNR were dem-
onstrated. However, the association of the clinical features of lymph 
node micrometastasis with prognosis showed diverse results, de-
pending on the pathological methods, the analysis methods, etc.; 
thus, it is difficult to derive concurrent results. Thus, more studies 
and comparative analyses are required.
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